Top Tweets for #davagi
That’s a wrap from Bermuda! #DAVAGI🌴✨ Inspired by the pace of progress across GI oncology, we close out four days of compelling science, evolving evidence, and thoughtful discussion, made possible by our outstanding faculty. Thank you all for sharing your time, research, expertise, and perspectives with us! 🙏🏝️
At #DAVAGI, Dr. @JanieYZhang @PittDeptofMed reviews MGMT in CRC, highlighting discordance between promoter methylation and protein expression, immune-evasive features of MGMT-high tumors, lower 3-year DFS, and the MGMT–Wnt/β-catenin link.
POLE loss-of-proofreading mutations are associated with ultra-high TMB and dramatic response to ICI. At #DAVAGI, Dr. @jpshen_md @UTMDAnderson highlights POLE P286R with TMB >100 mut/Mb, a near-complete response to ipilimumab/nivolumab, and median PFS of 2.1 months with standard frontline therapy in POLE LOP CRC.
At #DAVAGI, Dr. @BrunoBockorny @BIDMChealth presents KMT2C as a biomarker of increased sensitivity to platinum and immunotherapy. KMT2C defines an HRD-enriched population, while KMT2C-mutant GI cancers are enriched for MSI-H/TMB-high and showed prolonged PFS with immunotherapy; improved OS/PFS was seen with platinum.
Spotlight on biomarkers of immunotherapy response at #DAVAGI 🧬
Moderated by Dr. @skopetz @UTMDAnderson, the session “Biomarkers of Response to Immune Checkpoints” will explore factors associated with response to immune checkpoint therapy across GI cancers.
#BermudaGI2026 #GIOncology
Unstructured text in. Structured, source-linked data out. At #DAVAGI, Dr. @GIMedOnc @NorthwellHealth presents LUCID. Across seven clinical domains, accuracy ranged from 93–100%, with processing completed in 85 seconds per patient. The platform is being applied to clinical trial screening and molecular testing workflows.
Can AI-assisted navigation improve pancreatic cancer care delivery?
At #DAVAGI, Dr. @DrDanielKing @NorthwellHealth discusses an NLP-based pancreatic mass detection tool with 77% PPV and 94% sensitivity, integrated into a daily workflow. Implementation was associated with 72% vs 46% treated and 44% vs 27% receiving curative-intent therapy.
At #DAVAGI, Dr. @MDmanishshah @WeillCornell presents TESSERA, a foundation model trained on ~10,000 tumour genomes across 30+ cancer types, integrating mutations and copy-number patterns to support tumour classification, prognosis, and regimen selection, including first-line CRC and PDAC.
Spotlight on AI advances in GI oncology at #DAVAGI 💻
Moderated by Dr. @PMBolandMD @RutgersCancer, the session “Artificial Intelligence, Early Detection, and Digital Tools in GI Oncology” will explore emerging approaches in AI, early detection, and digital technologies across GI cancers.
#BermudaGI2026 #GIOncology
Dr. Kit Tam @UCDavisHealth discusses alisertib, an oral Aurora A kinase inhibitor, as a therapeutic strategy in pancreatic cancer. In Phase I, alisertib was safely administered in combination with full-dose gemcitabine. #DAVAGI
At #DAVAGI, Dr. Zachary Yeung @BannerHealth discusses NT-175, an engineered TCR targeting TP53 R175H, with activity in PDAC. TP53 R175H is reported in 4.2% of PDAC, and a 57% decrease in tumor burden at 3 months was observed.
At #DAVAGI, Dr. Devika Rao @MSKCancerCenter discusses atebimetinib + GnP as 1L therapy for mPDAC, highlighting Durability and Tolerability with deep cyclic MEK inhibition. In Phase II, median OS was 17.3 months, with no Grade 5 treatment-related AEs and Grade 3 rash in 5%.
At #DAVAGI, Dr. @Phase1Onc @OUHealth highlights biomarker findings from ARC-8 evaluating quemliclustat + gemcitabine/nab-paclitaxel ± zimberelimab in PDAC: high tumor NR4A expression was associated with improved OS, while maximal on-treatment NR4A downregulation was linked to T-cell activation and improved survival.
Dr. Sreenivasa Chandana of The Cancer & Hematology Centers discusses glucocorticoid receptor inhibition in pancreatic cancer and the Phase 2 TRIDENT study of relacorilant + nab-paclitaxel + gemcitabine in chemotherapy-naïve metastatic PDAC, currently in dose-finding. #DAVAGI
Spotlight on emerging targeted strategies at #DAVAGI 🎯
Moderated by Dr. Susanna Ulahannan(@Phase1Onc)(@OUHealth), the session “Emerging Targeted Approaches in Pancreatic Cancer”will explore new targeted therapies and evolving treatment strategies in pancreatic cancer.
#BermudaGI2026 #GIOncology
GPC3 is overexpressed in 70–80% of HCC. At #DAVAGI, Dr. Ian Hu @UTMDAnderson discusses GPC3-directed approaches, including CAR-T therapy (Ori-C101), bispecific antibodies (BGB-B2033), and theranostic radiopharmaceuticals, with a focus on actinium-225–based targeted therapy.
Targeting the stroma: two modalities, one target. At #DAVAGI, Dr. @BrunoBockorny @BIDMChealth reviews FAP-targeted ADC and radioligand approaches. In PDAC, OMTX705 + pembrolizumab showed 38% DCR; separately, LuMIERE and FiREBOLT highlight ongoing development of FAP radioligand therapy across solid tumors.
Spotlight on emerging science at #DAVAGI 🔬
Moderated by Dr. Tim Greten @theNCI, the session “Novel Theranostics and Other Emerging Approaches” will explore evolving biology, novel therapeutic strategies, and emerging approaches across GI oncology.
#BermudaGI2026 #GIOncology
Final morning at Bermuda GI 2026! 🌴☀️
The final day brings another lineup of expert perspectives, key insights, and engaging discussions across GI oncology.
#DAVAGI #BermudaGI2026 #GIOncology
Join us virtually:
https://t.co/vktPpzHxOQ
Supportive care must match the complexity of multidisciplinary GI oncology. Kelsey Lau-Min of @MassGeneralNews discusses tailored interventions in HCC, rectal cancer, and pancreatic cancer, including ongoing HARMONY and PATHWAYS pilot RCTs. #DAVAGI
Last Seen Hashtags on Sotwe
EmbeddedModems
Seen from United States
sevillismounido
Seen from United States
novinha ometv
Seen from Turkey
soutienpierre
Seen from United States
FullAccessArticle
Seen from United States
gfvip lucia renato
Seen from Italy
minichat #ometv
Seen from Turkey
mother
Seen from United States
محلي
Seen from Algeria
jillstuartendyrobe
Seen from United States
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.3M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.3M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.3M followers
Bill Gates
@billgates
65.1M followers
Selena Gomez
@selenagomez
63M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers